微泡
纤维蛋白
骨关节炎
医学
癌症研究
免疫学
化学
生物
病理
细胞生物学
作者
Zu Wan,Xin Wang,Zhenlan Fu,Fa Xu,Zonghan Wang,Yumengfei Huang,Xiongbo Song,Xin Tan,Gang Dai,Xiaojun Duan,Gong Xiaoyuan,Guangxing Chen,Liu Yang
标识
DOI:10.1016/j.jot.2026.101267
摘要
Osteoarthritis (OA) remains a major unmet clinical need. Exosomes from adipose-derived stem cells (ADSCs) show therapeutic potential but suffer from inconsistent efficacy. Here, we show that TLR3 activation of ADSCs with Poly(I:C) generates exosomes ( p Exos) with superior cartilage-protective capacity, as demonstrated in IL-1β-treated chondrocytes and a rat MIA-induced OA model. Proteomic profiling identified PSMD14, a 19S proteasome deubiquitinase, as a key cargo enriched in p Exos. Mechanistically, p Exos-delivered PSMD14 mediates K63-linked deubiquitination of fibrillarin (FBL), a nucleolar protein downregulated in OA chondrocytes, thereby stabilizing FBL and restoring ECM homeostasis. In human OA cartilage, FBL was markedly reduced in degenerated versus preserved regions, and modulating FBL expression in primary chondrocytes and explants directly affected ECM integrity, confirming clinical relevance. These findings establish the PSMD14-FBL axis as a therapeutic target and TLR3 priming as a simple, clinically feasible strategy to potentiate ADSC exosome therapy for OA. The translational potential of this article This study establishes TLR3 priming as a clinically feasible strategy to generate ADSC exosomes with defined therapeutic cargo. Poly(I:C) is a well-established clinical immune modulator and ADSCs can be readily isolated from lipoaspirate with widely available source. Moreover, the PSMD14-FBL axis identified herein represents a mechanistically grounded, druggable molecular target for exosome-based disease-modifying therapy in OA.
科研通智能强力驱动
Strongly Powered by AbleSci AI